Clinical Trial Update: Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab with radiation therapy for surgically resectable esophageal and gastroesophageal junction carcinomas; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Nasser Hanna, M.D. | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-04-28